Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer

Neoadjuvant chemotherapy (NAC) is a standard treatment option for locally advanced breast cancer. However, not all patients benefit from NAC; some even obtain worse outcomes after therapy. Hence, predictors of treatment benefit are crucial for guiding clinical decision-making. Here, we investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fengling, Yang, Yongquan, Wei, Yani, Zhao, Yuanyuan, Fu, Jing, Xiao, Xiuli, Zheng, Zhongxi, Bu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684483/
https://www.ncbi.nlm.nih.gov/pubmed/36418332
http://dx.doi.org/10.1038/s41523-022-00491-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684483/
https://www.ncbi.nlm.nih.gov/pubmed/36418332
http://dx.doi.org/10.1038/s41523-022-00491-1

Ejemplares similares